211 related articles for article (PubMed ID: 24428790)
1. Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice.
Lima-Júnior RC; Freitas HC; Wong DV; Wanderley CW; Nunes LG; Leite LL; Miranda SP; Souza MH; Brito GA; Magalhães PJ; Teixeira MM; Cunha FQ; Ribeiro RA
Br J Pharmacol; 2014 May; 171(9):2335-50. PubMed ID: 24428790
[TBL] [Abstract][Full Text] [Related]
2. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation.
Lima-Júnior RC; Figueiredo AA; Freitas HC; Melo ML; Wong DV; Leite CA; Medeiros RP; Marques-Neto RD; Vale ML; Brito GA; Oriá RB; Souza MH; Cunha FQ; Ribeiro RA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):931-42. PubMed ID: 22101361
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-18 as a target for modulation of irinotecan-induced intestinal toxicity: a step towards a better therapeutic index?: Commentary on Lima-Junior et al., Br J Pharmacol 171: 2335-2350.
Spyropoulos BG
Br J Pharmacol; 2015 Oct; 172(19):4779-81. PubMed ID: 24724613
[TBL] [Abstract][Full Text] [Related]
4. The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
Wong DV; Lima-Júnior RC; Carvalho CB; Borges VF; Wanderley CW; Bem AX; Leite CA; Teixeira MA; Batista GL; Silva RL; Cunha TM; Brito GA; Almeida PR; Cunha FQ; Ribeiro RA
PLoS One; 2015; 10(10):e0139985. PubMed ID: 26440613
[TBL] [Abstract][Full Text] [Related]
5. Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1β and IL-18 in mice.
Arifa RD; Madeira MF; de Paula TP; Lima RL; Tavares LD; Menezes-Garcia Z; Fagundes CT; Rachid MA; Ryffel B; Zamboni DS; Teixeira MM; Souza DG
Am J Pathol; 2014 Jul; 184(7):2023-34. PubMed ID: 24952429
[TBL] [Abstract][Full Text] [Related]
6. Role of regulatory T cells in irinotecan-induced intestinal mucositis.
Fernandes C; Wanderley CWS; Silva CMS; Muniz HA; Teixeira MA; Souza NRP; Cândido AGF; Falcão RB; Souza MHLP; Almeida PRC; Câmara LMC; Lima-Júnior RCP
Eur J Pharm Sci; 2018 Mar; 115():158-166. PubMed ID: 29307857
[TBL] [Abstract][Full Text] [Related]
7. A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice.
Pereira VB; Melo AT; Assis-Júnior EM; Wong DV; Brito GA; Almeida PR; Ribeiro RA; Lima-Júnior RC
Cancer Chemother Pharmacol; 2016 Feb; 77(2):323-32. PubMed ID: 26666645
[TBL] [Abstract][Full Text] [Related]
8. Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties.
Boeing T; de Souza P; Speca S; Somensi LB; Mariano LNB; Cury BJ; Ferreira Dos Anjos M; Quintão NLM; Dubuqoy L; Desreumax P; da Silva LM; de Andrade SF
Br J Pharmacol; 2020 May; 177(10):2393-2408. PubMed ID: 31976547
[TBL] [Abstract][Full Text] [Related]
9. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
Melo ML; Brito GA; Soares RC; Carvalho SB; Silva JV; Soares PM; Vale ML; Souza MH; Cunha FQ; Ribeiro RA
Cancer Chemother Pharmacol; 2008 Apr; 61(5):775-84. PubMed ID: 17624531
[TBL] [Abstract][Full Text] [Related]
10. TLR4 deficiency upregulates TLR9 expression and enhances irinotecan-related intestinal mucositis and late-onset diarrhoea.
Wong DVT; Holanda RBF; Cajado AG; Bandeira AM; Pereira JFB; Amorim JO; Torres CS; Ferreira LMM; Lopes MHS; Oliveira RTG; Pereira AF; Sant'Ana RO; Arruda LM; Ribeiro-Júnior HL; Pinheiro RF; Almeida PRC; Carvalho RF; Chaves FF; Rocha-Filho DR; Cunha FQ; Lima-Júnior RCP
Br J Pharmacol; 2021 Oct; 178(20):4193-4209. PubMed ID: 34216140
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial DNA as a Possible Ligand for TLR9 in Irinotecan-induced Small Intestinal Mucositis.
Ávila TV; Menezes-Garcia Z; do Nascimento Arifa RD; Soriani FM; Machado AMV; Teixeira MM; Fagundes CT; Souza DG
Immunol Invest; 2022 Aug; 51(6):1756-1771. PubMed ID: 35152824
[TBL] [Abstract][Full Text] [Related]
12. The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan.
Arifa RDN; Paula TP; Madeira MFM; Lima RL; Garcia ZM; Ÿvila TV; Pinho V; Barcelos LS; Pinheiro MVB; Ladeira LO; Krambrock K; Teixeira MM; Souza DG
Pharmacol Res; 2016 May; 107():102-110. PubMed ID: 26987941
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.
Logan RM; Gibson RJ; Bowen JM; Stringer AM; Sonis ST; Keefe DM
Cancer Chemother Pharmacol; 2008 Jun; 62(1):33-41. PubMed ID: 17703303
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.
Stringer AM; Gibson RJ; Bowen JM; Logan RM; Ashton K; Yeoh AS; Al-Dasooqi N; Keefe DM
Int J Exp Pathol; 2009 Oct; 90(5):489-99. PubMed ID: 19765103
[TBL] [Abstract][Full Text] [Related]
15. Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice.
Wang L; Wang R; Wei GY; Wang SM; Du GH
Biomed Pharmacother; 2020 Aug; 128():110262. PubMed ID: 32447214
[TBL] [Abstract][Full Text] [Related]
16. Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation.
Alvarenga EM; Souza LK; Araújo TS; Nogueira KM; Sousa FB; Araújo AR; Martins CS; Pacífico DM; de C Brito GA; Souza EP; Sousa DP; Medeiros JV
Chem Biol Interact; 2016 Dec; 260():129-140. PubMed ID: 27838229
[TBL] [Abstract][Full Text] [Related]
17. 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Yasuda M; Kato S; Yamanaka N; Iimori M; Matsumoto K; Utsumi D; Kitahara Y; Amagase K; Horie S; Takeuchi K
Br J Pharmacol; 2013 Mar; 168(6):1388-400. PubMed ID: 23072534
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
Ribeiro RA; Wanderley CW; Wong DV; Mota JM; Leite CA; Souza MH; Cunha FQ; Lima-Júnior RC
Cancer Chemother Pharmacol; 2016 Nov; 78(5):881-893. PubMed ID: 27590709
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of a lipid transfer protein isolated from Morinda citrifolia L. (noni) seeds on irinotecan-induced intestinal mucositis in mice.
do Carmo LD; de Fátima Pinheiro Rangel G; Rabelo LMA; de Fátima Goebel de Souza T; Júnior RCPL; Wong DVT; de Carvalho Leitão RF; da Silva AAV; Magalhães PJC; Costa AS; de Carvalho Oliveira Campos D; de Alencar NMN; de Oliveira HD
Naunyn Schmiedebergs Arch Pharmacol; 2022 Sep; 395(9):1097-1107. PubMed ID: 35776167
[TBL] [Abstract][Full Text] [Related]
20. Paraprobiotic Enterococcus faecalis EC-12 prevents the development of irinotecan-induced intestinal mucositis in mice.
Nobre LMS; da Silva Lopes MH; Geraix J; Cajado AG; Silva JMR; Ribeiro LR; Freire RS; Cavalcante DIM; Wong DVT; Alves APNN; Lima-Júnior RCP
Life Sci; 2022 May; 296():120445. PubMed ID: 35245522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
